GlassScriptPhysician profile
Beth A Rossi
NPI 1023256955
$1,449.88
in general payments reported to CMS, 2019-2025
13 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $148 · 2022: $145 · 2023: $362 · 2024: $299 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.69 |
| Education | $151.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $332.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $243.72 | 2022-2025 | Nucala |
| Genzyme Corporation | $180.59 | 2021-2025 | |
| Genentech USA, INC. | $164.81 | 2024-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $151.98 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $121.26 | 2022-2025 | Dupixent |
| Optinose US, INC. | $83.37 | 2021-2025 | |
| Cochlear Americas | $67.50 | 2024-2025 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Ars Pharmaceuticals Operations, INC. | $42.44 | 2025 | Neffy |
| Paratek Pharmaceuticals, INC. | $18.80 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $16.74 | 2023 | |
| Alk-Abello, INC | $13.61 | 2021 | |
| Phadia US INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.